We are live on ! Find out more

722 hedge funds and large institutions have $37.4B invested in DexCom in 2020 Q2 according to their latest regulatory filings, with 192 funds opening new positions, 251 increasing their positions, 223 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more first-time investments, than exits

New positions opened: 192 | Existing positions closed: 60

52% more capital invested

Capital invested by funds: $24.7B → $37.4B (+$12.8B)

22% more funds holding in top 10

Funds holding in top 10: 1822 (+4)

22% more funds holding

Funds holding: 593722 (+129)

13% more repeat investments, than reductions

Existing positions increased: 251 | Existing positions reduced: 223

7% more call options, than puts

Call options by funds: $463M | Put options by funds: $434M

0.04% more ownership

Funds ownership: 400.17%400.21% (+0.04%)

Holders
722
Holders Change
+129
Holders Change %
+21.75%
% of All Funds
14.8%
Holding in Top 10
22
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+22.22%
% of All Funds
0.45%
New
192
Increased
251
Reduced
223
Closed
60
Calls
$463M
Puts
$434M
Net Calls
+$29.7M
Net Calls Change
+$76.9M

DXCM Hedge Fund Activity: Q2 2020 in Review

722 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q2 2020, worth a combined $37.4B — up 52% from $24.7B a quarter earlier.

Buyers outnumbered sellers: 192 funds opened new DXCM positions and 60 closed out — a net gain of 132 holders — while 251 added to existing stakes and 223 trimmed.

The largest buyer was State Street, adding an estimated $658M. The largest seller was T. Rowe Price Associates, cutting an estimated $477M.

  • 722 institutional investors held DexCom (DXCM) as of Q2 2020, up from 593 in Q1 2020.
  • Funds reported $37.4B of DexCom stock for Q2 2020, up 52% quarter-over-quarter.
  • 192 funds opened new DexCom positions in Q2 2020 and 60 closed out, a net change of +132 holders.
  • The largest DexCom buyer in Q2 2020 was State Street, an estimated $658M added.
  • The largest DexCom seller in Q2 2020 was T. Rowe Price Associates, an estimated $477M sold.

Based on aggregated 13F filings for Q2 2020.